8 recruiting, 7 completed, 4 unknown, 3 withdrawn. 6 Phase 2, 5 Phase 1, 2 Early Phase 1, 2 Not applicable, 2 Phase 3.
Follow NMO Spectrum Disorder: new trials by email Literature Review of NMO Spectrum Disorder trials Research Report on NMO Spectrum Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Tongji NADs Cohort No active interventions - Multiple Sclerosis, NMO Spectrum Disorder | Not yet recruiting | Tongji Hospital | 1550 | 2026-03-01 | 2026-01-21 | |
| Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD) 10Hz tTIS (2-4mA) Intervention - NMO Spectrum Disorder | Not applicable | Recruiting | Tang-Du Hospital | 12 | 2025-12-08 | 2026-01-29 |
| Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD Mab Therapy - NMO Spectrum Disorder | Recruiting | Tongji Hospital | 200 | 2025-07-01 | 2025-09-08 | |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| A Study of RD06-04 in Patients With Active Autoimmune Diseases RD06-04 cell infusion - SLE, Sclerosis | Early Phase 1 | Withdrawn | Nanjing Bioheng Biotech Co., Ltd. | 2024-08-31 | 2026-02-03 | |
| FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Unknown | Tianjin Medical University General Hospital | 63 | 2024-07-05 | 2024-07-11 |
| Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. Multiple Sclerosis, NMO Spectrum Disorder | Recruiting | icometrix | 7000 | 2024-03-01 | 2025-12-12 | |
| ACT with NMOSD Patients and Caregivers Pilot Study Acceptance and Commitment Therapy - NMO Spectrum Disorder | Not applicable | Completed | Thomas Jefferson University | 43 | 2023-08-01 | 2025-01-07 |
| Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders Baricitinib - NMO Spectrum Disorder | Phase 1 | Active not recruiting | Tianjin Medical University General Hospital | 11 | 2023-04-15 | 2026-08-11 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| Sensitivity and Specificity of TSA-CBA for Autoantibodies Against Neural Antigen Determination CBA-TSA - NMO Spectrum Disorder, NMDA-R Encephalitis | Unknown | Beijing Tiantan Hospital | 2500 | 2022-06-30 | 2022-06-10 | |
| A Study of LP-168 in Healthy Volunteers LP-168 tablet, LP-168 Placebo tablet - Multiple Sclerosis, NMO Spectrum Disorder | Phase 1 | Completed | Guangzhou Lupeng Pharmaceutical Company LTD. | 70 | 2022-05-14 | 2023-02-24 |
| Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) B001 injection, Placebo - NMO Spectrum Disorder | Early Phase 1 | Recruiting | Shanghai Pharmaceuticals Holding Co., Ltd | 45 | 2022-04-07 | 2026-05-05 |
| China National Registry of Neuro-Inflammatory Diseases Intravenous steroid - Multiple Sclerosis, NMO Spectrum Disorder | Recruiting | Beijing Tiantan Hospital | 10000 | 2021-12-15 | 2023-07-21 | |
| Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Belimumab - NMO Spectrum Disorder | Phase 1 / Phase 2 | Completed | Tianjin Medical University General Hospital | 14 | 2021-12-12 | 2024-10-16 |
| Biorepository and Registry for Plasma Exchange Patients Antibody-mediated Rejection, NMO Spectrum Disorder | Recruiting | Charles M Knudson | 200 | 2021-07-28 | 2025-05-20 | |
| Imaging Evaluation of Central Nervous Autoimmune Diseases MRI - MS (Multiple Sclerosis), NMO Spectrum Disorder | Unknown | Qilu Hospital of Shandong University | 300 | 2021-05-01 | 2021-03-30 | |
| National, Multicentric Registry Study on Neuroimmunological Diseases in China Data collection and follow-up observation, Data collection - Multiple Sclerosis, NMO Spectrum Disorder | Unknown | Xuanwu Hospital, Beijing | 7000 | 2020-12-01 | 2024-06-05 | |
| Epidemiological Characteristics of COVID-19 in Patients With MS or NMO Evaluation of the epidemiological characteristics of coronavirus infection (SARS-CoV-2) - Multiple Sclerosis, NMO Spectrum Disorder | Completed | Assistance Publique - Hôpitaux de Paris | 2465 | 2020-04-17 | 2024-02-05 |
Showing 20 of 25. Sign in to see all of them.
Neuromyelitis Optica (25) · Multiple Sclerosis (8) · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (4) · Autoimmune Diseases of the Nervous System (3) · Myasthenia Gravis (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Encephalomyelitis, Acute Disseminated (2) · Myositis (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · COVID-19 (1) · Demyelinating Autoimmune Diseases, CNS (1) · Disease Progression (1) · Guillain-Barre Syndrome (1) · Immune System Diseases (1)
Cranial Nerve Diseases (25) · Demyelinating Diseases (25) · Eye Diseases (25) · Myelitis, Transverse (25) · Optic Nerve Diseases (25) · Optic Neuritis (25) · Autoimmune Diseases (24) · Demyelinating Autoimmune Diseases, CNS (24) · Immune System Diseases (24) · Nervous System Diseases (24) · Autoimmune Diseases of the Nervous System (22) · Pathological Conditions, Signs and Symptoms (8) · Pathologic Processes (7) · Disease Attributes (6) · Chronic Disease (5)
Azathioprine (2) · Cyclophosphamide (2) · Rituximab (2) · Acceptance and Commitment Therapy (1) · Antilymphocyte Serum (1) · Antirheumatic Agents (1) · Data Collection (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · HBM9161 (1) · Immunoglobulin G (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Mesna (1) · Methods (1)
Tianjin Medical University General Hospital (5) · Beijing Tiantan Hospital (3) · Tongji Hospital (2) · Assistance Publique - Hôpitaux de Paris (1) · Charles M Knudson (1) · First Affiliated Hospital of Guangxi Medical University (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · Mayo Clinic (1) · Michael, Levy M.D.,Ph.D. (1) · Nanjing Bioheng Biotech Co., Ltd. (1) · Northwestern University (1) · Qilu Hospital of Shandong University (1) · Shanghai Pharmaceuticals Holding Co., Ltd (1) · Tang-Du Hospital (1)
China (16) · United States (5) · Czechia (1) · France (1) · Germany (1)
Anastasia Vishnevetsky, MD, PhD (1) · Friedemann Paul, PhD, MD (1) · Fu-Dong Shi, MD,PhD (1) · Jinliang Chen, PhD (1) · Junwei Hao, MD (1) · Michael Levy, MD, PhD (1) · Qiang Liu, M.D.,Ph.D (1) · Qiang Liu, M.D.,PhD (1) · Richard Burt, MD (1) · Sean J Pittock, M.D. (1) · Wei Qiu (1) · Yaou Liu, PhD (1) · Yulan Tang (1)
PMID 33469828, PMID 38453475, PMID 39250723, PMID 40489809, PMID 40716235, PMID 41506767, PMID 42079612